Cargando…

Identification of repurposable drugs with beneficial effects on glucose control in type 2 diabetes using machine learning

Despite effective medications, rates of uncontrolled glucose levels in type 2 diabetes remain high. We aimed to test the utility of machine learning applied to big data in identifying the potential role of concomitant drugs not taken for diabetes which may contribute to lowering blood glucose. Succe...

Descripción completa

Detalles Bibliográficos
Autores principales: Koren, Gideon, Nordon, Galia, Radinsky, Kira, Shalev, Varda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864406/
https://www.ncbi.nlm.nih.gov/pubmed/31763043
http://dx.doi.org/10.1002/prp2.529
_version_ 1783471879145652224
author Koren, Gideon
Nordon, Galia
Radinsky, Kira
Shalev, Varda
author_facet Koren, Gideon
Nordon, Galia
Radinsky, Kira
Shalev, Varda
author_sort Koren, Gideon
collection PubMed
description Despite effective medications, rates of uncontrolled glucose levels in type 2 diabetes remain high. We aimed to test the utility of machine learning applied to big data in identifying the potential role of concomitant drugs not taken for diabetes which may contribute to lowering blood glucose. Success in controlling blood glucose was defined as achieving HgA1c levels < 6.5% after 90‐365 days following diagnosis and initiating treatment. Among numerous concomitant drugs taken by type 2 diabetic patients, alpha 1 (α1)‐adrenoceptor antagonist drugs were the only group of medications that significantly improved the success rate of glucose control. Searching the published literature, this effect of α1‐adrenoceptor antagonists has been shown in animal models, where this class of medications appears to induce insulin secretion. In conclusion, machine learning of big data is a novel method to identify effective antidiabetic effects for potential repurposable medications already on the market for other indications. Because these α1‐adrenoceptor antagonists are widely used in men for treating benign prostate hyperplasia (BPH) at age groups exhibiting increased rates of type 2 diabetes, this finding is of potential clinical significance.
format Online
Article
Text
id pubmed-6864406
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68644062019-11-22 Identification of repurposable drugs with beneficial effects on glucose control in type 2 diabetes using machine learning Koren, Gideon Nordon, Galia Radinsky, Kira Shalev, Varda Pharmacol Res Perspect Original Articles Despite effective medications, rates of uncontrolled glucose levels in type 2 diabetes remain high. We aimed to test the utility of machine learning applied to big data in identifying the potential role of concomitant drugs not taken for diabetes which may contribute to lowering blood glucose. Success in controlling blood glucose was defined as achieving HgA1c levels < 6.5% after 90‐365 days following diagnosis and initiating treatment. Among numerous concomitant drugs taken by type 2 diabetic patients, alpha 1 (α1)‐adrenoceptor antagonist drugs were the only group of medications that significantly improved the success rate of glucose control. Searching the published literature, this effect of α1‐adrenoceptor antagonists has been shown in animal models, where this class of medications appears to induce insulin secretion. In conclusion, machine learning of big data is a novel method to identify effective antidiabetic effects for potential repurposable medications already on the market for other indications. Because these α1‐adrenoceptor antagonists are widely used in men for treating benign prostate hyperplasia (BPH) at age groups exhibiting increased rates of type 2 diabetes, this finding is of potential clinical significance. John Wiley and Sons Inc. 2019-11-20 /pmc/articles/PMC6864406/ /pubmed/31763043 http://dx.doi.org/10.1002/prp2.529 Text en © 2019 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Koren, Gideon
Nordon, Galia
Radinsky, Kira
Shalev, Varda
Identification of repurposable drugs with beneficial effects on glucose control in type 2 diabetes using machine learning
title Identification of repurposable drugs with beneficial effects on glucose control in type 2 diabetes using machine learning
title_full Identification of repurposable drugs with beneficial effects on glucose control in type 2 diabetes using machine learning
title_fullStr Identification of repurposable drugs with beneficial effects on glucose control in type 2 diabetes using machine learning
title_full_unstemmed Identification of repurposable drugs with beneficial effects on glucose control in type 2 diabetes using machine learning
title_short Identification of repurposable drugs with beneficial effects on glucose control in type 2 diabetes using machine learning
title_sort identification of repurposable drugs with beneficial effects on glucose control in type 2 diabetes using machine learning
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864406/
https://www.ncbi.nlm.nih.gov/pubmed/31763043
http://dx.doi.org/10.1002/prp2.529
work_keys_str_mv AT korengideon identificationofrepurposabledrugswithbeneficialeffectsonglucosecontrolintype2diabetesusingmachinelearning
AT nordongalia identificationofrepurposabledrugswithbeneficialeffectsonglucosecontrolintype2diabetesusingmachinelearning
AT radinskykira identificationofrepurposabledrugswithbeneficialeffectsonglucosecontrolintype2diabetesusingmachinelearning
AT shalevvarda identificationofrepurposabledrugswithbeneficialeffectsonglucosecontrolintype2diabetesusingmachinelearning